XML 19 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8
Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)
6 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended
Jun. 30, 2013
Sep. 30, 2013
Segment
Vendor
Sep. 30, 2012
Aug. 31, 2012
Financing Agreement with Biopharma
Jun. 30, 2013
Specialty pharmacy
Customer
Sep. 30, 2013
Minimum
Sep. 30, 2013
Maximum
Aug. 31, 2012
Maximum
Financing Agreement with Biopharma
Accounting Policies [Line Items]                
Additional cash and cash equivalents, description   We consider all highly liquid investments purchased with maturities of three months or less from the date of purchase to be cash equivalents.            
Percentage of sales to one specialty pharmacy customer 97.00%              
Number of customer         1      
Number of manufacturer   1            
Property and equipment, estimated useful life           3 years 5 years  
Debt issuance date       Aug. 02, 2012        
Proceeds from issuance of long-term obligation, net of cash paid for issuance costs     $ 29,860,000 $ 30,000,000        
Total amount to be paid related to debt               $ 45,000,000
Payment terms for discount on sales of Korlym sales 30 days              
Product returns period prior to expiration date to provide credit   6 months            
Product returns period after expiration date to provide credit   12 months            
Number of operating segment   1            
Probability percentage for achieving performance-based vesting criteria for expense recognition           70.00%